Stocks · News reference

8-K filing — Tenaya Therapeutics, Inc. (TNYA)

Jul 2, 2026, 9:00 PMSEC EDGAR

Filed: 2026-07-02 AccNo: 0001193125-26-294879 Size: 153 KB Item 1.02: Termination of a Material Definitive Agreement

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 5, 2026, 10:39 PMBenzinga Newsdesk
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of $(0.14) per share
Read original at benzinga
TNYA
BenzingaJun 29, 2026, 12:36 PMBenzinga Newsdesk
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13
Read original at benzinga
TNYA
BenzingaJun 2, 2026, 8:32 PMBenzinga Newsdesk
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
Read original at benzinga
TNYA